{"id":45250,"date":"2022-06-20T13:01:30","date_gmt":"2022-06-20T11:01:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/"},"modified":"2022-06-20T13:01:30","modified_gmt":"2022-06-20T11:01:30","slug":"phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/","title":{"rendered":"Phreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium"},"content":{"rendered":"
\n

RALEIGH, N.C.–(BUSINESS WIRE)–Phreesia is proud to announce that Hilary Hatch, PhD, the company\u2019s Chief Clinical Officer, has been selected to participate in the National Quality Forum (NQF)\u2019s 2022 Leadership Consortium. Dr. Hatch\u2019s inclusion in this expert group underscores Phreesia\u2019s commitment to improving patients\u2019 healthcare experiences and outcomes by enabling them to become more active participants in their care.\n<\/p>\n

<\/a><\/p>\n

\nThe Leadership Consortium is a prestigious and exclusive forum of multistakeholder healthcare experts representing NQF Member Organizations, where they share their collective thought leadership to identify actionable strategies to improve healthcare quality and drive lasting change in key areas. The group\u2019s guidance informs the direction of NQF programs and drives improvement across healthcare.\n<\/p>\n

\n\u201cIt\u2019s an honor to be included among this group of distinguished leaders in healthcare,\u201d said Dr. Hatch. \u201cAs a psychologist, I am excited by the growing movement toward person-centered care and health equity, and proud to have the opportunity to champion the patient voice in quality.\u201d\n<\/p>\n

\nDr. Hatch leads the development of clinical programs at Phreesia. She partners with clinical leaders at health systems, medical groups and other organizations to improve quality performance through the implementation of patient-reported outcomes (PROs), social determinants of health (SDOH) and behavioral health needs screenings, and patient activation modules.\n<\/p>\n

\nPhreesia\u2019s platform facilitates more than 100 million visits a year, collecting key patient-reported data for healthcare providers. Phreesia is also the steward of the Patient Activation Measure\u00ae (PAM\u00ae), a survey that assesses patients\u2019 underlying knowledge, skills and confidence to manage their own health. PAM is backed by research demonstrating that higher scores are associated with better clinical outcomes, higher patient satisfaction with care and lower healthcare costs. PAM has also been successfully used as a performance metric, PAM-PM, which has been endorsed by the NQF.\n<\/p>\n

\nThe members of the Leadership Consortium will discuss six urgent issues in the current healthcare landscape, including the collection and use of SDOH data and the improvement of patient safety in ambulatory care settings. The group will prioritize one topic as a focus area, then collectively identify and recommend improvement opportunities to be tested during the Implementation Collaborative throughout 2023.\n<\/p>\n

\n\u201cNQF has become an integral component of American healthcare\u2019s efforts to improve the safety, quality, and efficiency of care delivery,\u201d said Leadership Consortium Co-Chair Peter Angood, MD, President & CEO, American Association for Physician Leadership. \u201cThe Leadership Consortium continues to address significantly important topic areas by identifying the issues of concern, and then providing actionable solutions and next steps for helping to refine approaches on these various topic areas. By doing so, the Leadership Consortium itself is now becoming an important and influential group within healthcare.\u201d\n<\/p>\n

\nAbout Phreesia<\/span><\/b>\n<\/p>\n

\nPhreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their healthcare and provides a modern, convenient experience, while enabling our clients to enhance clinical care and drive efficiency.\n<\/p>\n

\nForward-looking Statements<\/span><\/b>\n<\/p>\n

\nThis press release includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These statements include, but are not limited to, statements regarding our ability to enable patients to become more active in their care and improve health outcomes. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. In some cases, you can identify forward-looking statements by the following words: \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing,\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our products and services; our ability to maintain the security and availability of our platform; our ability to make accurate predictions about our industry; and our ability to attract, retain and cross-sell to healthcare services clients. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in our filings with the Securities and Exchange Commission (\u201cSEC\u201d), including our Annual Report on Form 10-K for the fiscal year ended January 31, 2022, as updated by our subsequently filed Quarterly Reports on Form 10-Q, and other SEC filings. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:
\n
\n<\/b>
Annie Harris
\n
aharris@phreesia.com<\/a>
929-526-2611\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

RALEIGH, N.C.–(BUSINESS WIRE)–Phreesia is proud to announce that Hilary Hatch, PhD, the company\u2019s Chief Clinical Officer, has been selected to participate in the National Quality Forum (NQF)\u2019s 2022 Leadership Consortium. Dr. Hatch\u2019s inclusion in this expert group underscores Phreesia\u2019s commitment to improving patients\u2019 healthcare experiences and outcomes by enabling them to become more active participants … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-45250","format-standard","category-industry"],"yoast_head":"\nPhreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"RALEIGH, N.C.–(BUSINESS WIRE)–Phreesia is proud to announce that Hilary Hatch, PhD, the company\u2019s Chief Clinical Officer, has been selected to participate in the National Quality Forum (NQF)\u2019s 2022 Leadership Consortium. Dr. Hatch\u2019s inclusion in this expert group underscores Phreesia\u2019s commitment to improving patients\u2019 healthcare experiences and outcomes by enabling them to become more active participants ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-20T11:01:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220620005081\/en\/1490543\/21\/PhreesiaCircle.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Phreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium\",\"datePublished\":\"2022-06-20T11:01:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/\"},\"wordCount\":929,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005081\\\/en\\\/1490543\\\/21\\\/PhreesiaCircle.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/\",\"name\":\"Phreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005081\\\/en\\\/1490543\\\/21\\\/PhreesiaCircle.jpg\",\"datePublished\":\"2022-06-20T11:01:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005081\\\/en\\\/1490543\\\/21\\\/PhreesiaCircle.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005081\\\/en\\\/1490543\\\/21\\\/PhreesiaCircle.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/","og_locale":"en_US","og_type":"article","og_title":"Phreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium - Pharma Trend","og_description":"RALEIGH, N.C.–(BUSINESS WIRE)–Phreesia is proud to announce that Hilary Hatch, PhD, the company\u2019s Chief Clinical Officer, has been selected to participate in the National Quality Forum (NQF)\u2019s 2022 Leadership Consortium. Dr. Hatch\u2019s inclusion in this expert group underscores Phreesia\u2019s commitment to improving patients\u2019 healthcare experiences and outcomes by enabling them to become more active participants ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-20T11:01:30+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220620005081\/en\/1490543\/21\/PhreesiaCircle.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Phreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium","datePublished":"2022-06-20T11:01:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/"},"wordCount":929,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220620005081\/en\/1490543\/21\/PhreesiaCircle.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/","url":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/","name":"Phreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220620005081\/en\/1490543\/21\/PhreesiaCircle.jpg","datePublished":"2022-06-20T11:01:30+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220620005081\/en\/1490543\/21\/PhreesiaCircle.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220620005081\/en\/1490543\/21\/PhreesiaCircle.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/phreesias-hilary-hatch-named-to-the-nqf-2022-leadership-consortium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Phreesia\u2019s Hilary Hatch Named to the NQF 2022 Leadership Consortium"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45250"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45250\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}